Cumberland Pharmaceutical... (CPIX)
4.24
0.18 (4.43%)
At close: Apr 14, 2025, 3:59 PM
4.39
3.54%
After-hours: Apr 14, 2025, 07:23 PM EDT
4.43% (1D)
| Bid | 3.57 |
| Market Cap | 59.23M |
| Revenue (ttm) | 37.87M |
| Net Income (ttm) | -6.48M |
| EPS (ttm) | -0.46 |
| PE Ratio (ttm) | -9.22 |
| Forward PE | 16.86 |
| Analyst | n/a |
| Ask | 4.39 |
| Volume | 12,284 |
| Avg. Volume (20D) | 1,487,531 |
| Open | 3.92 |
| Previous Close | 4.06 |
| Day's Range | 3.92 - 4.25 |
| 52-Week Range | 1.04 - 7.25 |
| Beta | -0.24 |
About CPIX
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxat...
Sector Healthcare
IPO Date Aug 11, 2009
Employees 91
Stock Exchange NASDAQ
Ticker Symbol CPIX
Website https://www.cumberlandpharma.com
1 month ago
+28.42%
Cumberland Pharmaceuticals shares are trading high...
Unlock content with
Pro Subscription
2 months ago
+76.53%
Cumberland Pharmaceuticals shares are trading higher after the company announced advance results from the Phase 2 Fight DMD trial in Duchenne muscular dystrophy heart disease.
1 month ago · seekingalpha.com
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call TranscriptCumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Molly Aggas – Account Supervisor-Dalton Agency A.J. Kazimi – Chief Executi...
